Search Results
H-ASP-PHE-OH 25 mg | Purity Not Available
TargetMol
H-ASP-PHE-OH 50 mg | Purity Not Available
TargetMol
LY2090314 10 mg | 99.88%
TargetMol
LY2090314, an effective GSK-3α/β inhibitor (IC50: 1.5 nM/0.9 nM), may improve the efficacy of platinum-based chemotherapy regimens. LY2090314 has been used in trials studying the treatment of Leukemia, Advanced Cancer, and Pancreatic Cancer.
More Information Supplier PageLY2090314
LY2090314 100 mg | 99.88%
TargetMol
LY2090314, an effective GSK-3α/β inhibitor (IC50: 1.5 nM/0.9 nM), may improve the efficacy of platinum-based chemotherapy regimens. LY2090314 has been used in trials studying the treatment of Leukemia, Advanced Cancer, and Pancreatic Cancer.
More Information Supplier PageLY2090314
Pimobendan 5 mg | 99.84%
TargetMol
Pimobendan 50 mg | 99.84%
TargetMol
Pimobendan 10 mg | 99.84%
TargetMol
H-ASP-PHE-OH 5 mg | Purity Not Available
TargetMol
H-ASP-PHE-OH
Valganciclovir hydrochloride 100 mg | Purity Not Available
TargetMol
Valganciclovir Hydrochloride is a hydrochloride salt form of valganciclovir, a prodrug form of ganciclovir, a nucleoside analog of 2′-deoxyguanosine, with antiviral activity. After phosphorylation, valganciclovir is incorporated into DNA, resulting in inhibition of viral DNA polymerase, and viral replication.
More Information Supplier PageValganciclovir hydrochloride
